Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice

Peer Review reports

Original Submission
26 Feb 2019	Submitted	Original manuscript
27 Apr 2019	Reviewed	Reviewer Report - Tamara Matysiak-Budnik
21 May 2019	Reviewed	Reviewer Report - Arvind Dasari
6 Jul 2019	Author responded	Author comments - Gemma Bruera
Resubmission - Version 2
6 Jul 2019	Submitted	Manuscript version 2
14 Sep 2019	Reviewed	Reviewer Report - Tamara Matysiak-Budnik
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
29 Sep 2019	Editorially accepted
16 Oct 2019	Article published	10.1186/s12885-019-6214-z

Back to article page